Pfizer in 2005
|
|
ICMR HOME | Case Studies Collection
To download Pfizer in 2005 case study
(Case Code: BSTA120) click on the button below, and select the case from the list of available cases:
OR
Buy With PayPal
|
» Business Strategy Case Studies
» Case Studies Collection
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
Case Details: |
Price: |
| Case Code |
: |
BSTA120 |
Electronic Format: Rs.
300;
Courier (within India):Rs. 25 Extra
Themes- |
| Case Length |
: |
15 Pages |
| Period |
: |
1849-2005 |
| Organization |
: |
- |
| Pub Date |
: |
2005 |
| Teaching Note |
: |
Not Available |
| Countries
|
: |
USA |
| Industry |
: |
Pharmaceuticals |
Abstract:
|
The world's largest research-based pharmaceuticals firm, Pfizer is well known
for its blockbuster drugs such as the pain management drug Celebrex, erectile
dysfunction therapy Viagra, and cholesterol-lowering Lipitor. Pfizer's biggest
challenge currently is patent expiration. The company has already warned
investors it will probably lose some $14 billion due to patent expirations by
2007. Besides, the sales of some of Pfizer's blockbuster drugs such as Viagra
and Lipitor are declining due to intensifying competition from other drug
makers. Pfizer is also moving in a direction that will pit it against biotech
companies such as Onyx, Genentech. Will Pfizer be able to find alternative
sources of revenue? Will Pfizer's forays into biotech succeed?
|
|
Contents:
Keywords:
Pfizer, research-based pharmaceuticals firm, pain management drug Celebrex, Viagra, Lipitor, Pfizer's patent expiration, Pfizer's blockbuster drugs and Pfizer's forays into biotec
Pfizer in 2005
- Next Page>>
|
|
